Istituto di Ricerche Farmacologiche "Mario Negri"

Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Italy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Kidney Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Case-Control Studies Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Odds Ratio Medicine & Life Sciences
Confidence Intervals Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Profiles

No photo of Diego Albani

Diego Albani

Person: Academic

19992018
No photo of Renzo Bagnati

Renzo Bagnati

Person: Academic

19872017
No photo of Claudia Balducci

Claudia Balducci

Person: Academic

19962019

Projects 2018 2018

MARIO NEGRI - STUDI FARMACOLOGICI E CLINICI NELLE MALATTIE NEUROLOGICHE

Ricerca, U.

1/1/18 → 12/30/18

Project: Other project

MARIO NEGRI - STUDI FARMACOLOGICI E CLINICI NELLE MALATTIE RARE

Ricerca, U.

1/1/18 → 12/30/18

Project: Other project

MARIO NEGRI - STUDI FARMACOLOGICI E CLINICI SU PATOLOGIE ASSOCIATE AD ESPOSIZIONE AMBIENTALE CON PARTICOLARE RIFERIMENTO ALLE MALATTIE RENALI CRONICHE

Ricerca, U.

1/1/18 → 12/30/18

Project: Other project

Research Output 1952 2018

ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells

Portale, F., Cricrì, G., Bresolin, S., Lupi, M., Gaspari, S., Silvestri, D., Russo, B., Marino, N., Ubezio, P., Pagni, F., Vergani, P., Te Kronnie, G., Valsecchi, M. G., Locatelli, F., Rizzari, C., Biondi, A., Dander, E. & D'Amico, G., Sep 27 2018, In : Haematologica.

Research output: Contribution to journal › Article

B-Lymphoid Precursor Cells
Leukemia
Bone Marrow
Aptitude
Mesenchymal Stromal Cells
5 Citations

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

GIM Investigators, Apr 1 2018, In : The Lancet Oncology. 19, 4, p. 474-485 12 p.

Research output: Contribution to journal › Article

exemestane
letrozole
Tamoxifen
Aromatase Inhibitors
Breast Neoplasms

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Maugeri Centre for Telehealth and Telecare (MCTT), 2018, In : The Lancet Oncology. 19, 4, p. 474-485 12 p.

Research output: Contribution to journal › Article